Previous 10 | Next 10 |
Believes Company’s Board has Abandoned its Fiduciary Duties by Choosing to Sell Progenics at Massive Discount in Attempt to Prevent the Voices of Shareholders from Being Heard Views Progenics’ Potential Value Under Appropriate Leadership to be Substantially Higher Tha...
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) to Lantheus Holdings, Inc. (“Lantheus”) for 0.2502 shares of Lantheus stock for each share of Pr...
Shares of Lantheus Holdings (NASDAQ: LNTH) , a company focused on diagnostic medical imaging equipment and supplies , dropped 21% as of 10:35 a.m. EDT on Wednesday after the company announced that it is acquiring Progenics Pharmaceuticals (NASDAQ: PGNX) , a commercial-stage biotechnology ...
Savara (NASDAQ: SVRA ) -57% after FDA rejects Molgradex. More news on: Savara Inc., United Natural Foods, Inc., Avianca Holdings S.A., Stocks on the move, Read more ...
Lantheus Holdings (NASDAQ: LNTH ) agrees to acquire Progenics (NASDAQ: PGNX ) in an all-stock transaction, adding targeted medicines and artificial intelligence to find, fight, an follow cancer to its portfolio. More news on: Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., Heal...
Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus’ Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company’s Innovative Diagnostic and Radiopharmaceutic...
Board Has Made Numerous Corporate Governance Enhancements Reflecting Feedback From Shareholders No Shareholder Action Required at this Time NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted ...
Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board’s Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current Board’s Actions Following Stockholder Vote Results Calli...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting PyL TM ( 18 F-DCFPyL) has been...
News, Short Squeeze, Breakout and More Instantly...
Progenics Pharmaceuticals Inc. Company Name:
PGNX Stock Symbol:
NASDAQ Market:
Progenics Pharmaceuticals Inc. Website:
The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...
Biopharma Dynavax Technologies (NASDAQ: DVAX) is one of many companies racing to develop a COVID-19 vaccine. Like many coronavirus-focused companies, Dynavax has seen its shares rise on the ongoing concern related to the pandemic -- in its case, by 50% year to date. While investors may co...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it...